Minimized Carryover Using BioResolve™ Protein A Affinity Columns

Significance of the topic

Protein A affinity chromatography is a cornerstone technique for monoclonal antibody (mAb) titer measurement and initial capture in bioprocessing. However, carryover of bound product or process-derived impurities between injections undermines titer accuracy, increases cross-contamination risk, and accelerates column fouling and lifetime loss. Minimizing carryover therefore improves analytical sensitivity, data integrity, and operational economics—particularly important when columns are reused across multiple campaigns or products.

Objectives and study overview

This application brief evaluated the carryover performance of Waters BioResolve Protein A Affinity Columns versus a commercially available benchmark. The goal was to quantify carryover after a defined mAb injection and blank elution cycles, compare results across resin batches and hardware lots, and assess whether specific column geometries further reduce detectable carryover.

Methodology

• Test analyte: 1 µg NISTmAb loaded in Dulbecco’s PBS.
• Elution buffer: 100 mM potassium phosphate + 100 mM potassium chloride, pH 3.
• Instrumental sequence: three load/elute gradient cycles appended in a single injection to produce two successive blank elutions. This design bypassed the sample manager to ensure measured carryover originated solely from the column.
• Timing per cycle: 1.0 min load/wash, 0.1 min shift to elution, 1.0 min elution hold, 0.1 min return to load buffer, 1.0 min re-equilibration.
• Columns and flow rates: 2.1 × 20 mm BioResolve columns at 1 mL/min and 3.9 × 5 mm BioResolve columns at 2 mL/min.
• Sampling: multiple resin batches and High Performance Surface (HPS) hardware lots were evaluated. A commercially available on-market Protein A column served as benchmark.

Instrumentation

• BioResolve Protein A 3.5 µm stationary phase packed into HPS column hardware in two formats: 2.1 × 20 mm and 3.9 × 5 mm.
• Chromatography system configured to perform appended elution cycles within a single injection (method-specific timing and gradients as above).
• Use of NISTmAb as a standardized test material to enable consistent carryover assessment.

Main results and discussion

• Across twelve resin batches tested in the 2.1 × 20 mm format, average carryover was 0.58% on the first blank elution and 0.25% on the second blank elution following a 1 µg injection.
• The benchmark column tested in this study showed higher carryover: 1.79% on the first blank and 0.65% on the second blank, indicating that BioResolve columns reduced carryover by approximately 65% under the method used.
• Seven 2.1 × 20 mm columns packed from a single resin batch but differing in HPS hardware lots produced similar averages (0.52% and 0.25%), indicating reproducibility across hardware lots.
• Notably, all tested 3.9 × 5 mm BioResolve columns produced no detectable carryover under the same experimental conditions, including a column packed with a resin batch that had exhibited measurable carryover in the 2.1 × 20 mm format. This suggests column geometry and packing in the 3.9 × 5 mm format confer an inherent advantage for minimizing carryover despite lower linear velocity.
• Figure summary: a bar-graph comparison (described in the original brief) showed mean carryover and standard errors for the tested groups; the 3.9 × 5 mm BioResolve group had no detectable carryover, and the 2.1 × 20 mm BioResolve group had substantially lower means than the benchmark.
• Interpretation: improved performance likely arises from a combination of resin chemistry, optimized packing in HPS hardware, and column geometry. Reduced non-specific interactions with hardware surfaces and more efficient elution from the ligand surface are plausible contributors. The observed performance is method-specific and depends on elution conditions, residence time, and system configuration.

Benefits and practical applications

• Lower or non-detectable carryover increases confidence in titer quantification and reduces false-positive contributions from prior injections.
• Minimized cross-contamination risk is especially valuable in multi-product or multiproduct-development environments where reuse of affinity columns can reduce costs.
• Reduced fouling potential extends effective column lifetime and lowers total cost of ownership for Protein A affinity media, which are typically more expensive than other chromatographic resins.
• High-throughput formats such as 3.9 × 5 mm enable rapid analysis with negligible carryover, supporting routine titer monitoring, process development, and QC workflows without need for dedicated single-product columns in some cases.

Limitations and considerations

• This document is an application brief and lacks a full experimental methods section; reported values are method-specific and may vary with different elution conditions, sample loads, or system configurations.
• Benchmarking here covers one commercially available competitor; broader benchmarking across more vendors and larger sample sets would strengthen generalizability.
• Carryover measurement used 1 µg NISTmAb; behavior may differ with higher loads, diverse mAb constructs, or presence of challenging impurities.

Future trends and applications

• Standardized carryover testing protocols for Protein A columns will enable better cross-platform comparisons and adoption of best practices.
• Column hardware and surface engineering (e.g., advanced HPS treatments) will continue to reduce non-specific adsorption and fouling.
• Integration of inline sensors or rapid QC assays to monitor carryover in real time could inform dynamic cleaning cycles and product-specific reuse strategies.
• Development of ligands and packing geometries optimized for both high throughput and low carryover will support multi-product facilities and reduce capital expense from dedicated columns.
• Combined strategies—improved resin chemistry, geometry, and automated cleaning-in-place (CIP) sequences—will further lower detection limits and enable reliable reuse across varied mAb products.

Conclusion

Waters BioResolve Protein A Affinity Columns, evaluated under the method conditions in this brief, demonstrate substantially reduced carryover relative to a commercial benchmark, with the 3.9 × 5 mm format showing no detectable carryover after a 1 µg NISTmAb injection. This improvement supports more accurate titer determination, lowers cross-contamination risk, and can extend column service life—benefits that are valuable for both development and routine QC workflows. Users should note that carryover is method- and system-dependent and that additional validation under specific operational conditions is recommended.

Reference

1. Helle S., et al. (2024) Carryover analysis by liquid chromatography mass spectrometry in a multiproduct resin reuse context. Process Biochemistry 146:547–559.
2. Lute S., Brorson K. (2009) Bacteriophage and impurity carryover and total organic carbon release during extended protein A chromatography. Journal of Chromatography A 1216(18):3774–3783.
3. Pathak M., Rathore A.S. (2016) Mechanistic understanding of fouling of protein A chromatography resin. Journal of Chromatography A 1459:78–88.
4. Ravi N., Huerta J., Ferreira G. (2023) Evaluating multiproduct chromatography Protein A resin reuse for monoclonal antibodies in biopharmaceutical manufacturing. Biotechnology Progress 39(3).
5. Mahajan E., Werber J., Kothary K., Larson T. (2013) One Resin, Multiple Products: A Green Approach to Purification. In: Kantardjieff A., Asuri P., Coffman J.L., Jayapal K. (eds) Developments in Biotechnology and Bioprocessing. American Chemical Society, Washington, DC, pp. 87–111.